Drug Target Review
JULY 13, 2023
In recent years, a novel approach known as condensate biology has emerged, revolutionising the way researchers think about drug discovery and development. Dewpoint Therapeutics, a platform drug discovery company founded in 2018, has been at the forefront of this exciting field.
Drug Target Review
NOVEMBER 1, 2023
2018 Jun 13;5. Role of autotaxin in cancer stem cells. 2018 Sep;37(2–3):509–18. Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production. The Journal of Cell Biology. References: Ninou I, Magkrioti C, Aidinis V. Frontiers in Medicine.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Target Review
MARCH 3, 2025
Turning this tide, Professor Jens Christian Schwamborn, a cell biology expert at the University of Luxembourg and co-founder of OrganoTherapeutics , is leading a groundbreaking effort to transform our understanding and treatment of these debilitating diseases.
Drug Target Review
OCTOBER 31, 2023
When I was studying cell biology, looking at how cells divide, I couldn’t fathom how math could possibly fit into that. My undergraduate studies focused on biochemistry and cell biology, so very much STEM-based, but my professors and mentors noticed my penchant for critical thinking which led me to consider law.
Drug Target Review
AUGUST 24, 2023
She joined the company in November 2018 with more than 10 years of experience in drug discovery and non-clinical development of immunomodulatory drugs in the immuno-oncology space. Shear forces induce ICAM-1 nanoclustering on endothelial cells that impact on T-cell migration. Current Opinion in Cell Biology.
The Pharma Data
DECEMBER 1, 2020
Innate Pharma’s commercial-stage product, Lumoxiti, in-licensed from AstraZeneca in the US, EU and Switzerland, was approved by the FDA in September 2018. Lumoxiti is a first-in class specialty oncology product for hairy cell leukemia.
NIH Director's Blog: Drug Development
SEPTEMBER 20, 2018
2018 Jun;558(7711):553-558. [2] 2018 Apr;93(4):251-258. [3] Kang Y, Kuybeda O, de Waal PW, Mukherjee S, Van Eps N, Dutka P, Zhou XE, Bartesaghi A, Erramilli S, Morizumi T, Gu X, Yin Y, Liu P, Jiang Y, Meng X, Zhao G, Melcher K, Ernst OP, Kossiakoff AA, Subramaniam S, Xu HE. Many Targe Sriram K, Insel PA. Mol Pharmacol.
Expert insights. Personalized for you.
98 
Let's personalize your content